234 patents currently held
38 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
11 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
43
Ending by 2030
Nov 2026
Next term end
159
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2036 · High confidence
Also notable
Ends Dec 2029 · Medium confidence
Also notable
Ends Mar 2031 · Medium confidence
Also notable
Ends Nov 2037 · High confidence
Also notable
Ends Aug 2035 · High confidence
Also notable
Ends Aug 2033 · High confidence
Also notable
Ends Dec 2029 · High confidence
Also notable
Ends Nov 2034 · Medium confidence
EZH2 Inhibitors for Treating Lymphoma
US 11,642,347
Cited by 11 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2036.
Intermediates and Methods for the Synthesis of Halichondrin B Analogs
US 8,987,479
Cited by 59 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
Compounds Useful in the Synthesis of Halichondrin B Analogs
US 8,927,597
Cited by 56 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Macrocyclic Compound and Uses Thereof
US 9,938,288
The most cited patent in this portfolio, cited by 69 later US patents, top 5% of utility patents granted in 2018 in our data. Protection runs to 2037.
High-Purity Quinoline Derivative and Method for Manufacturing Same
US 10,259,791
Cited by 26 later US patents, top 10% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2035.
Tetrahydropyrazolopyrimidine Compounds
US 9,126,999
Cited by 56 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Benzoxazole Compounds and Methods of Use
US 8,354,400
Cited by 29 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Macrocyclization Reactions and Intermediates Useful in the Synthesis of Analogs of Halichondrin B
US 10,221,189
Cited by 20 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2034.
Formerly held, still cited
Notable
Ends Apr 2032 · High confidence
Cited by 51 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
now held by Epizyme, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 26 to 30, 2026 · next Nov 26
- 4 fees due Dec 4 to 20, 2026 · next Dec 4
- 3 fees due Jan 4 to 25, 2027 · next Jan 4
- 1 fee due Feb 15, 2027The maintenance fee for Macrocyclic Compound and Uses Thereof (US 11,725,015) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 7 fees due Mar 8 to 22, 2027 · next Mar 8
- 3 fees due Apr 1 to 29, 2027 · next Apr 1
- 2 fees due May 3 to 14, 2027 · next May 3
- 6 fees due Jun 3 to 24, 2027 · next Jun 3
- 3 fees due Jul 5 to 21, 2027 · next Jul 5
- 2 fees due Aug 4 to 18, 2027 · next Aug 4
- 1 fee due Sep 12, 2027The maintenance fee for Certain Pladienolide Compounds and Methods of Use (US 11,926,619) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 5 fees due Oct 2 to 14, 2027 · next Oct 2
- 3 fees due Nov 5 to 10, 2027 · next Nov 5
Recent changes
- Oct 16Assignment recorded on 1 record: Spidel, Jared and 9 others to Eisai R&D Management Co., Ltd. Recorded Oct 16, 2026, executed Feb 26, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76408, frame 650.
- 7 of the patents on this record were granted since Aug 21, 2026
- 8 terms have ended since Aug 21, 2026
What they patent
The largest of its 159 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,504,746 | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide In force · High confidence | In force | High confidence | |
| US 7,532,136 | Analog to Digital Converter Unit In force · High confidence | In force | High confidence | |
| US RE46,965 | Intermediates for the Preparation of Analogs of Halichondrin B In force · Low confidence | In force | Low confidence | |
| US 8,481,565 | Method for Stabilizing Anti-Dementia Drug In force · Medium confidence | In force | Medium confidence | |
| US 7,550,483 | Amorphous Salt of 4-(3-Chiloro-4-(CYCLOPROPLYLAMINOCARBONYL)AMINOPHENOXY)-7-Method-6-Quinolinecarboxamide and Process for Preparing the Same In force · High confidence | In force | High confidence | |
| US 9,006,256 | Antitumor Agent for Thyroid Cancer In force · Medium confidence | In force | Medium confidence | |
| US 9,931,295 | Stabilized Pharmaceutical Composition In force · High confidence | In force | High confidence | |
| US 7,691,882 | Heterocycles Substituted Pyridine Derivatives and Antifungal Agent Containing Thereof In force · High confidence | In force | High confidence | |
| US 8,058,444 | Heterocycle-Substituted Pyridine Derivative's Salt or Crystal Thereof In force · High confidence | In force | High confidence | |
| US 8,137,926 | Kit for Assaying EPHA4 Processing by Gamma-Secretase In force · High confidence | In force | High confidence |
Also on record, not counted in the 234: 38 patents in force now held by others · 354 patents ended · 87 applications pending · 335 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.